253 related articles for article (PubMed ID: 28801885)
1. Active Surveillance for Intermediate Risk Prostate Cancer.
Klotz L
Curr Urol Rep; 2017 Aug; 18(10):80. PubMed ID: 28801885
[TBL] [Abstract][Full Text] [Related]
2. Management of intermediate-risk prostate cancer with active surveillance: never or sometimes?
Masic S; Washington SL; Carroll PR
Curr Opin Urol; 2017 May; 27(3):231-237. PubMed ID: 28234748
[TBL] [Abstract][Full Text] [Related]
3. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.
Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG
BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899
[TBL] [Abstract][Full Text] [Related]
4. Regular transition zone biopsy during active surveillance for prostate cancer may improve detection of pathological progression.
Wong LM; Toi A; Van der Kwast T; Trottier G; Alibhai SM; Timilshina N; Evans A; Zlotta A; Fleshner N; Finelli A
J Urol; 2014 Oct; 192(4):1088-93. PubMed ID: 24742593
[TBL] [Abstract][Full Text] [Related]
5. Active Surveillance for Prostate Cancer: How to Do It Right.
Garisto JD; Klotz L
Oncology (Williston Park); 2017 May; 31(5):333-40, 345. PubMed ID: 28512731
[TBL] [Abstract][Full Text] [Related]
6. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer.
Klotz L; Vesprini D; Sethukavalan P; Jethava V; Zhang L; Jain S; Yamamoto T; Mamedov A; Loblaw A
J Clin Oncol; 2015 Jan; 33(3):272-7. PubMed ID: 25512465
[TBL] [Abstract][Full Text] [Related]
7. Outcomes of initially expectantly managed patients with low or intermediate risk screen-detected localized prostate cancer.
Bul M; van den Bergh RC; Zhu X; Rannikko A; Vasarainen H; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1672-7. PubMed ID: 22928973
[TBL] [Abstract][Full Text] [Related]
8. Active surveillance in males with low- to intermediate-risk localized prostate cancer: A modern prospective cohort study.
Rakauskas A; Tawadros T; Lucca I; Herrera F; Bourhis J; Burruni R; Gomes MN; Codeluppi C; Jolliet L; La Rosa S; Meuwly JY; Jichlinski P; Berthold D; Valerio M
Investig Clin Urol; 2021 Jul; 62(4):416-422. PubMed ID: 34190436
[TBL] [Abstract][Full Text] [Related]
9. Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.
Vellekoop A; Loeb S; Folkvaljon Y; Stattin P
J Urol; 2014 Feb; 191(2):350-7. PubMed ID: 24071481
[TBL] [Abstract][Full Text] [Related]
10. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
[TBL] [Abstract][Full Text] [Related]
11. Defining Intermediate Risk Prostate Cancer Suitable for Active Surveillance.
Loeb S; Folkvaljon Y; Bratt O; Robinson D; Stattin P
J Urol; 2019 Feb; 201(2):292-299. PubMed ID: 30240688
[TBL] [Abstract][Full Text] [Related]
12. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
13. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
[TBL] [Abstract][Full Text] [Related]
14. Predictors of pathologic progression on biopsy among men on active surveillance for localized prostate cancer: the value of the pattern of surveillance biopsies.
Cary KC; Cowan JE; Sanford M; Shinohara K; Perez N; Chan JM; Meng MV; Carroll PR
Eur Urol; 2014 Aug; 66(2):337-42. PubMed ID: 24035632
[TBL] [Abstract][Full Text] [Related]
15. A negative confirmatory biopsy among men on active surveillance for prostate cancer does not protect them from histologic grade progression.
Wong LM; Alibhai SM; Trottier G; Timilshina N; Van der Kwast T; Zlotta A; Lawrentschuk N; Kulkarni G; Hamilton R; Ferrara S; Margel D; Trachtenberg J; Jewett MA; Toi A; Evans A; Fleshner NE; Finelli A
Eur Urol; 2014 Sep; 66(3):406-13. PubMed ID: 23664820
[TBL] [Abstract][Full Text] [Related]
16. Updated clinical results of active surveillance of very-low-risk prostate cancer in Korean men: 8 years of follow-up.
Ha JY; Shin TJ; Jung W; Kim BH; Park CH; Kim CI
Investig Clin Urol; 2017 May; 58(3):164-170. PubMed ID: 28480341
[TBL] [Abstract][Full Text] [Related]
17. Active surveillance for intermediate-risk prostate cancer: yes, but for whom?
Overland MR; Washington SL; Carroll PR; Cooperberg MR; Herlemann A
Curr Opin Urol; 2019 Nov; 29(6):605-611. PubMed ID: 31436567
[TBL] [Abstract][Full Text] [Related]
18. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
[TBL] [Abstract][Full Text] [Related]
19. Transperineal Template-guided Mapping Biopsy Identifies Pathologic Differences Between Very-Low-risk and Low-risk Prostate Cancer: Implications for Active Surveillance.
Merrick GS; Delatore A; Butler WM; Bennett A; Fiano R; Anderson R; Adamovich E
Am J Clin Oncol; 2017 Feb; 40(1):53-59. PubMed ID: 25068472
[TBL] [Abstract][Full Text] [Related]
20. Factors influencing disease progression of prostate cancer under active surveillance: a McGill University Health Center cohort.
Barayan GA; Brimo F; Bégin LR; Hanley JA; Liu Z; Kassouf W; Aprikian AG; Tanguay S
BJU Int; 2014 Dec; 114(6b):E99-E104. PubMed ID: 24684511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]